{
  "docId": "019de075-e341-775b-a82c-decdaeb5c03e",
  "docSlug": "c5ed60c4cc85a094dbae2fa13cb26a34",
  "documentTitle": "Alkermes | Investor Presentation Deck | 37 slides",
  "authorId": "alkermes",
  "authorName": "Mural Oncology",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 37,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a numbered list format to present five key highlights about the company's spin-off status, cytokine portfolio, and specific drug program progress.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/5",
  "deckHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e",
  "deckJsonHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json",
  "deckAnchorHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.06,
        "y": 0.23
      },
      "kind": "list",
      "text": "1. Mural Oncology is the oncology business of Alkermes plc; Mural Oncology is expected to be separated into a new, independent publicly traded company via a spin-off in 4Q 2023. Two key data readouts anticipated within 18 months\n2. Portfolio of novel, investigational cytokines engineered to optimize the “known knowns” of native interleukins – retain their high potency while potentially overcoming their low tolerability\n3. Nemvaleukin is an intrinsically active, stable fusion protein which does not degrade into native-IL-2 and is designed to selectively bind to the intermediate-affinity IL-2 receptor, enabling a potentially enhanced therapeutic window\n4. Nemvaleukin has generated compelling clinical data to date, with durable responses¹ in monotherapy and in PD-1 combination across a range of tumor types. Exploring alternative dosing regimens. ARTISTRY-6 and ARTISTRY-7 readouts both expected in 1Q 2025²\n5. IL-18 and IL-12 programs in preclinical development with potentially differentiated therapeutic properties and leveraging advanced protein engineering capabilities. Candidate nominations expected in 2024",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4bd8788b-0709-428c-8a19-7c41f7f858e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.06,
        "y": 0.87
      },
      "kind": "source-note",
      "text": "1. Durable response defined as a response with a duration that exceeds the response generally observed with standard of care treatment; in the context of high unmet disease states such as mucosal melanoma and platinum-resistant ovarian cancer (“PROC”), a response that exceeds six months is considered durable\n2. Subject to patient enrollment",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a8409b6-4e10-46d9-9acc-3a7eb61e2a07",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.42,
        "x": 0.06,
        "y": 0.12
      },
      "kind": "title",
      "text": "Mural Oncology - Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f25125e7-80c7-48fd-982a-4487a60f7c1f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}